Xamoterol, sold under the brand names Corwin, Carwin, Corwil, and Xamtol among others, is a cardiac stimulant which is used in the treatment of heart failure. It acts as a selective partial agonist of the ò<sub>1</sub>-adrenergic receptor with around 50% intrinsic sympathomimetic activity (ISA) (i.e., intrinsic activity). The drug has no significant ò<sub>2</sub>-adrenergic receptor agonistic activity. Xamoterol provides cardiac stimulation at rest but acts as a blocker during exercise. It is taken by mouth.
Xamoterol is not available in the United States. It is marketed in the United Kingdom, Austria, Belgium, and Luxembourg.
Xamoterol is a hydrophilic compound with a predicted log P of -0.31 to -1.11. Due to its hydrophilicity, xamoterol does not cross the bloodâÂÂbrain barrier and has no central nervous system effects. Hence, it is a peripherally selective drug.